Efficacy and Safety Evaluation of Rifapentine and Rifampicin in the Treatment of Pulmonary Tuberculosis  

作　　者：HUANGSongmei 

机构地区：[1]YanjiCityHospital,JilinProvince,YanbianJilin133000,China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第7期121-125,共5页

摘　　要：Objective: to evaluate the clinical effect and safety of rifamentine and rifampin in tuberculosis. Methods: patients admitted with confirmed pulmonary tuberculosis were included in the study. A total of 80 cases were collected from October 2020 to October 2021. Computer equiwas randomly divided into two groups of 40 cases. Both groups received symptomatic anti-tuberculosis treatment, while the observation and control groups were treated with rifamentine and rifampicin, respectively. Summarize and compare the clinical effect and safety of different drugs. Results: the effectiveness of the rifampin treatment group was significantly higher than the rifampin group, the results confirmed that the improvement effect of the negative, lesion absorption, cavity closure, and low drug-related adverse effects after treatment, and the group is relatively low in IFN-γ, CA125 and IL-6 index, the contrast has significant differences (P <0.05). Conclusion: tuberculosis in routine treatment at the same time, the use of rifampin and rifampittin can achieve the purpose of treatment of both, but compared with the two, rifampittin treatment effectiveness is relatively high, can improve the body inflammation level, promote combining lesion absorption and empty closure, another drug biggest advantage is high safety, with clinical promotion and application value.

关 键 词：rifamentine RIFAMPICIN tuberculosis treatment EFFICACY SAFETY 

分 类 号：R521[医药卫生—内科学]